All News
Should you repeat the dsDNA? SMART-SLE study
>3400 SLE pts, > 37,582 visits. Pts with fluctuating + results or persistently + had higher rates of SLE flares HR 1.56 (95% CI 1.3-1.87, p< 0.001). Inc or Dec dsDNA Ab > 2X from last visit can predict flares @rheumnow #ACR22 abst#0327
TheDaoIndex KDAO2011 ( View Tweet)
❤️ Beta Blockers in LV-GCA
📚65 pts LV-GCA
💊 15(23%) on BB, 50(73%) not
🩻 new aortic dilatation on serial imaging in 15 (23%) - ALL in those NOT on beta blocker 💔
More studies needed, but supportive initial data 🔥
@RheumNow #ACR22 Abst#0477
Patricia Harkins DrTrishHarkins ( View Tweet)
#abs0127 #acr22 @rheumnow 59 adults pts from SAPHO-CNO Study (SCS) reported high scores (0.8 or >SD) for pain interference& fatigue domains vs general population. ⬇️ score on PROMIS physical function; 72.9% of subjects had a T-score < 45. https://t.co/5QfwlB98wV
Olga Petryna DrPetryna ( View Tweet)
#ACR22 Abstr#0769 In patients on DMARDs who didnt seroconvert after primary mRNA COVID vac, is switching to vector or booster with mRNA more effective? An RCT (N=46) showed more pts receiving booster mRNA seroconverted (63%) vs vector (18%). Tcell response was similar @RheumNow https://t.co/5GTsdhNUQZ
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Barajas-Ochoa et al. Gender representation in editorial boards of rheum journals. Only 28% women editors overall. Clear discrepancies between journals. Well done @ACR_Journals ! @rheumnow #ACR22 Abstr#104 https://t.co/dpElAUSEuS https://t.co/rDAG6HwNf4
Richard Conway RichardPAConway ( View Tweet)
Neural networks help distinguish between inflammatory arthritis, RA vs PsA, based on MRI inflammatory patterns, focusing on regions of clinical relevance. Fascinating use of tech that needs to be further evaluated clinically. Abs 0242 #ACR22 @RheumNow https://t.co/EMJZkFaMwu https://t.co/hNf70PaZX6
Dr. Rachel Tate uptoTate ( View Tweet)
❓Vessel wall MRI superior to TA-US in c-GCA❓
🔥In c-GCA vessel wall MRI examines beyond the temporal arteries -
✅more 🧠 cranial arteries, including occipital arteries and the all important 👁 orbital structures
Abst#0473
#ACR22 @RheumNow @RennieRhee https://t.co/ayuPP5v7Lh
Patricia Harkins DrTrishHarkins ( View Tweet)
Tune in to Twitter, Facebook or LinkedIn daily at 5pm ET! #ACR22 https://t.co/BPlVx0rRCd
Dr. John Cush RheumNow ( View Tweet)
Prieto-Pena et al. Tocilizumab in GCA and TAK. Observational study of 70 GCA, 57 TAK in Spain. Similar efficacy in both diseases. @rheumnow #ACR22 Abstr#0465 https://t.co/pyKAILryhH https://t.co/Csp7FIgnzD
Richard Conway RichardPAConway ( View Tweet)
After bDMARD treatment for 1 year in AxSpA, the gut microbiota composition:
◦ more resembled controls
◦ Enrichment of Collinsella remained stable
◦ Depletion of some species in HLA-B27+ patients from baseline
https://t.co/Mw4MToqFcQ
Poddubnyy et al @ProftDr #ACR22 @RheumNow
Dr. Antoni Chan synovialjoints ( View Tweet)
#ACR22 Abs 0256 identified different autoantibodies in ACPA+ and ACPA– RA. Study shows potential utility of serum autoantibodies as diagnostic targets for RA subgroups & treatments. This study reminds me of @RheumNow teaching that not all RA created equal. https://t.co/Fjjk6uC0pB https://t.co/Ozr32cJojr
Dr. Rachel Tate uptoTate ( View Tweet)
“It's not that I'm so smart, it's just that I stay with problems longer.” Einstein
Love the quote in the community hub for early career @NIAMSFunding - Perseverance is the KEY in this funding world #ACR22 @RheumNow
Bella Mehta bella_mehta ( View Tweet)
Figueroa-Parra et al @AliDuarteMD Preventative services in SLE better in some areas and worse in some than comparators. Overall cervical screening, osteoporosis, dyslipidaemia low in this high risk group @rheumnow #ACR22 Abstr#0064 https://t.co/fHQ7ct6yt5 https://t.co/x7gHUDA8zo
Richard Conway RichardPAConway ( View Tweet)
Wilding et al. Mortality in AAV 1/5/10-year survival 90%/73%/57% in AAV, 97%/86%/73% controls (p <0.0001). Highest 1st year - often vasculitis related (35%). After this - infection (28% vs 19%) @rheumnow #ACR22 Abstr#0448 https://t.co/YwwaaB6jDS https://t.co/ogrJkLAd1v
Richard Conway RichardPAConway ( View Tweet)
Good news for patients who require short interruptions in biologic therapy!
Majority of axSpA patients (82%) who restarted ixekizumab after withdrawing, achieved low disease activity and 68% eventually had inactive disease.
#Abs0427 @RheumNow #ACR22
Robert B Chao, MD doctorRBC ( View Tweet)
Hajj-Ali @RulaHajjAliMD et al. Worse PROs neuro AAV. Lower SF-36 Physical Functioning, Limitations in Physical role, Bodily Pain, and PCS. Higher PROMIS pain, lower PROMIS function @rheumnow #ACR22 Abstr#0437 https://t.co/ldC2VEZ0FV https://t.co/0pdjdSZQSS
Richard Conway RichardPAConway ( View Tweet)
Ab0192: UPA vs ADA vs PBO on RAPID3 in SELECT-PsA (bio-naive, P3 trial) #ACR22
UPA>ADA from wk 16-56. UPA and ADA>>PBO
Strongly associates with DAPSA or MDA/VLDA composite scores
@RheumNow https://t.co/ABY12ar7RS
Eric Dein ericdeinmd ( View Tweet)
Kakoullis et al. Steroid initiation within 1 week onset of GCA symptoms associated decreased relapse OR=0.216. @rheumnow #ACR22 Abstr#0469 https://t.co/sEW1V6NRpb https://t.co/4sAYZbmHX3
Richard Conway RichardPAConway ( View Tweet)
Korean KOBIO-AS registry: Infection incidence 26 events/1000 PY (URI > zoster most common) Risks: ischemic heart disease, ASDAS-ESR >3.5, complicated DM, abnormal chest x-ray, current bDMARDs. Male gender was protective. Abs 0372 #ACR22 @RheumNow https://t.co/i1JyFuriFz
Dr. Rachel Tate uptoTate ( View Tweet)
Christ et al. 1 year follow up of GUSTO - tocilizumab monotherapy in GCA after 3 days only of steroid. Week 52 - 13/18 in relapse free remission. Week 104 12/18 in relapse free remission @rheumnow #ACR22 Abstr#0470 #ACRbest https://t.co/Pnvoeqb8rp https://t.co/dB6F25Krgg
Richard Conway RichardPAConway ( View Tweet)